Glucocorticosteroid-induced complications in patients with idiopathic thrombocytopenic purpura

Glucocorticosteroid-induced complications in patients with idiopathic thrombocytopenic purpura

Glucocorticosteroids (GCS) are the first-line treatment for idiopathic thrombocytopenic purpura (ITP). Despite their high efficacy in patients with newly diagnosed ITP, an adequate level of platelets remains after GCS withdrawal in only less than 20 % of patients. Additionally, GCS use is associated...

Full description

Saved in:
Bibliographic Details
Main Authors: S. G. Zakharov, T. A. Mitina, A. V. Zakharova, R. V. Vardanyan, E. V. Kataeva, Yu. B. Chernykh, L. L. Vysotskaya, L. V. Ivanitskiy, I. N. Kontievskiy, O. P. Madzyara, O. R. Zhuravlev, N. V. Gorgun, Z. M. Kharasova
Format: Article
Language:Russian
Published: ABV-press 2023-12-01
Series:Онкогематология
Subjects:
glucocorticoid
side effect
adverse event
idiopathic thrombocytopenic purpura
thrombopoietin receptor agonists
avatrombopag
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/883
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucocorticosteroids (GCS) are the first-line treatment for idiopathic thrombocytopenic purpura (ITP). Despite their high efficacy in patients with newly diagnosed ITP, an adequate level of platelets remains after GCS withdrawal in only less than 20 % of patients. Additionally, GCS use is associated with an increased risk of different adverse reactions, including serious and life-threatening ones. Thrombopoietin receptor agonists represent a relatively new class of drugs for treating ITP as a second-line therapy. This paper reviews the risks of GCS pharmacotherapy, as well as the evidence supporting the use of thrombopoietin receptor agonists as both first-line and second-line treatment for patients with ITP.
ISSN:1818-8346
2413-4023

Similar Items